Additional European Equity News - 30th September 2026
European equity updates on 30 September 2026 include Admiral's buyback, Bayer's orphan drug designations, Greggs' Q3 sales growth, Unite's site disposal, German energy directives, and broker rating changes.
News detail
Admiral Group (ADM LN) - Co. begins GBP 45mln share buyback programme. (Admiral) Bayer (BAYN GY) - Co. announces that its lemiretprocel has received orphan drug designations from the US FDA and the EU EMA for treating syndromic and non-syndromic inherited retinal disorders. (Bayer) German Energy - Germany's Economics Minister has reportedly told SEFE to increase its natural gas capacity, Handelsblatt reports. (Handelsblatt) Greggs (GRG LN) - Q3 Trading Update: Total Sales +7.7%, LFL Sales +3.4%. Says the improved trading reflects the success of continued menu innovation along with more settled weather and continues to expect around 100 to 110 net new shop openings in 2026. (Greggs) Unite Group (UTG LN) - Co. announces the sale of its 444-bed King's Place development site to an affiliate of Far East Orchard for GBP 60mln. (Unite) Commerzbank (CBK GY) downgraded to Hold from Buy at Deutsche Bank Julius Baer (BAER SW) upgraded to Equal Weight from Underweight at Morgan Stanley Lindt (LISN SW) reiterated with Sell at Goldman Sachs
What do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.